TY  - GEN
AU  - Reckamp,Karen L
AU  - Gardner,Brian K
AU  - Figlin,Robert A
AU  - Elashoff,David
AU  - Krysan,Kostyantyn
AU  - Dohadwala,Mariam
AU  - Mao,Jenny
AU  - Sharma,Sherven
AU  - Inge,Landon
AU  - Rajasekaran,Ayyappan
AU  - Dubinett,Steven M
TI  - Tumor response to combination celecoxib and erlotinib therapy in non-small cell lung cancer is associated with a low baseline matrix metalloproteinase-9 and a decline in serum-soluble E-cadherin
SN  - 1556-1380
PY  - 2008///0416
KW  - Antineoplastic Combined Chemotherapy Protocols
KW  - pharmacology
KW  - Biomarkers, Tumor
KW  - blood
KW  - Cadherins
KW  - Carcinoma, Non-Small-Cell Lung
KW  - drug therapy
KW  - Celecoxib
KW  - Chemokines, CC
KW  - Cyclooxygenase Inhibitors
KW  - Dose-Response Relationship, Drug
KW  - Drug Resistance, Neoplasm
KW  - ErbB Receptors
KW  - antagonists & inhibitors
KW  - Erlotinib Hydrochloride
KW  - Humans
KW  - Lung Neoplasms
KW  - Macrophage Inflammatory Proteins
KW  - Matrix Metalloproteinase 9
KW  - Protein Kinase Inhibitors
KW  - Pyrazoles
KW  - administration & dosage
KW  - Quinazolines
KW  - Sulfonamides
KW  - Tissue Inhibitor of Metalloproteinase-1
N1  - Publication Type: Clinical Trial, Phase I; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
UR  - https://doi.org/10.1097/JTO.0b013e3181622bef
ER  -